PL3801460T3 - Sole amlodypiny do stosowania miejscowego w leczeniu chorób odbytu i odbytnicy - Google Patents
Sole amlodypiny do stosowania miejscowego w leczeniu chorób odbytu i odbytnicyInfo
- Publication number
- PL3801460T3 PL3801460T3 PL19766349.5T PL19766349T PL3801460T3 PL 3801460 T3 PL3801460 T3 PL 3801460T3 PL 19766349 T PL19766349 T PL 19766349T PL 3801460 T3 PL3801460 T3 PL 3801460T3
- Authority
- PL
- Poland
- Prior art keywords
- anus
- rectum
- diseases
- treatment
- topical use
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679137P | 2018-06-01 | 2018-06-01 | |
| US201962822400P | 2019-03-22 | 2019-03-22 | |
| PCT/IB2019/000689 WO2019229535A2 (en) | 2018-06-01 | 2019-05-29 | Topical amlodipine salts for the treatment of anorectal diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3801460T3 true PL3801460T3 (pl) | 2025-09-08 |
Family
ID=67928855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19766349.5T PL3801460T3 (pl) | 2018-06-01 | 2019-05-29 | Sole amlodypiny do stosowania miejscowego w leczeniu chorób odbytu i odbytnicy |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US11197848B2 (pl) |
| EP (1) | EP3801460B1 (pl) |
| JP (1) | JP7530354B2 (pl) |
| KR (1) | KR20210023908A (pl) |
| CN (1) | CN112423736A (pl) |
| AU (1) | AU2019276832B2 (pl) |
| BR (1) | BR112020024395A2 (pl) |
| CA (1) | CA3102228A1 (pl) |
| CO (1) | CO2020016480A2 (pl) |
| CR (1) | CR20200630A (pl) |
| ES (1) | ES3030705T3 (pl) |
| HU (1) | HUE072422T2 (pl) |
| IL (1) | IL279121B2 (pl) |
| MX (1) | MX2020012949A (pl) |
| NZ (1) | NZ771464A (pl) |
| PL (1) | PL3801460T3 (pl) |
| SG (1) | SG11202012365QA (pl) |
| WO (1) | WO2019229535A2 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3102228A1 (en) | 2018-06-01 | 2019-12-05 | Tavanta Therapeutics Hungary Incorporated | Topical amlodipine salts for the treatment of anorectal diseases |
| ES2978421T3 (es) * | 2019-12-09 | 2024-09-12 | Futura Medical Developments Ltd | Composición tópica y métodos para medir la capacidad de enfriamiento de una composición tópica |
| US11253474B1 (en) | 2021-02-01 | 2022-02-22 | Liqmeds Worldwide Limited | Pharmaceutical solution of amlodipine |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT89837B (pt) | 1988-02-29 | 1994-01-31 | Pfizer | Processo para a preparacao de composicoes para aumentar o fluxo transdermico contendo uma 1-alquilazaciclo-heptan-2-ona ou uma cis-olefina |
| WO1995006466A1 (en) | 1993-09-01 | 1995-03-09 | Koren Laboratories Pty. Limited | Treatment of anorectal disorders |
| US8048875B1 (en) | 1997-02-24 | 2011-11-01 | S.L.A. Pharma Ag | Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker |
| EP1250927A3 (en) * | 1997-02-24 | 2003-03-26 | S.L.A. Pharma AG | Pharmaceutical composition for topical application comprising nifedipine |
| WO1999018957A1 (en) * | 1998-03-26 | 1999-04-22 | Reddy-Cheminor, Inc. | Stable pharmaceutical composition containing amlodipine besylate and atenolol |
| US6391869B1 (en) | 1998-12-14 | 2002-05-21 | Cellergy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
| IL143726A0 (en) * | 1998-12-14 | 2002-04-21 | Cellegy Pharma Inc | A pharmaceutical composition containing a nitric oxide donor |
| IL129102A0 (en) * | 1999-03-22 | 2000-02-17 | J P M E D Ltd | An emulsion |
| IL137275A0 (en) | 2000-07-12 | 2001-07-24 | Yosefus Azaria | Pharmaceutical composition for the treatment of anal fissures |
| US8425892B2 (en) | 2001-10-29 | 2013-04-23 | Columbia Laboratories, Inc. | Extended, controlled-release pharmaceutical compositions using charged polymers |
| WO2003075851A2 (en) | 2002-03-06 | 2003-09-18 | Cellegy Pharmaceuticals, Inc. | Compositions and methods for the treatment of anorectal disorders |
| EP1893396A2 (en) * | 2005-05-09 | 2008-03-05 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| WO2008022032A2 (en) | 2006-08-11 | 2008-02-21 | Solvay Pharmaceuticals, Inc. | Topical pharmaceutical compositions comprising calcium-channel blocker and method of using same |
| EP2061463A4 (en) * | 2006-09-01 | 2010-01-20 | Moberg Derma Ab | TOPICAL COMPOSITION WITH A DIHYDROPYRIDINCALCIUM ANTAGONIST |
| EP2167045B1 (en) * | 2007-06-08 | 2017-08-09 | University of Virginia Patent Foundation | Topical poloxamer formulations for enhancing microvascular flow: compositions and uses thereof |
| JP5072748B2 (ja) * | 2007-07-10 | 2012-11-14 | 株式会社 メドレックス | アムロジピンの安定な液剤とゼリー剤 |
| CN101468001A (zh) * | 2007-12-29 | 2009-07-01 | 北京瑞康医药技术有限公司 | 含有氨氯地平系列盐和他汀类药物的治疗组合物 |
| US8686040B2 (en) | 2008-03-31 | 2014-04-01 | Rdd Pharma Ltd. | Method for treating anal pruritis and other perianal disorders |
| JP2009256216A (ja) * | 2008-04-14 | 2009-11-05 | Towa Yakuhin Kk | 溶液状態で安定なアムロジピンベシル酸塩内服用液剤 |
| AU2009310437A1 (en) * | 2008-10-31 | 2010-05-06 | Moberg Derma Ab | Topical composition comprising a combination of at least two penetration enhancing agents |
| GB0906868D0 (en) * | 2009-04-21 | 2009-06-03 | Rabin Bennie | Amlodipine salt compositions |
| WO2011075655A1 (en) | 2009-12-18 | 2011-06-23 | Exodos Life Sciences Limited Partnership | Methods and compositions for treating peripheral vascular disease |
| US10471131B2 (en) * | 2012-01-19 | 2019-11-12 | Hybrid Medical, Llc | Topical therapeutic formulations |
| JP2015517518A (ja) | 2012-05-17 | 2015-06-22 | コントラクト ファーマシューティカルズ リミテッド | カルシウムチャネル遮断薬の非イオン性ベシクル製剤 |
| RU2592366C2 (ru) | 2013-07-22 | 2016-07-20 | Общество с ограниченной ответственностью "ХИЛИНГ ФАРМ" | Фармакологическая композиция для лечения проктологических заболеваний (варианты) |
| WO2015051336A1 (en) | 2013-10-03 | 2015-04-09 | David Wise | Compositions and methods for treating pelvic pain and other conditions |
| WO2016118040A1 (ru) | 2015-01-21 | 2016-07-28 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" | Гель, содержащий нифедипин и лидокаина гидрохлорид, его применение и способ приготовления с использованием нанотехнологий |
| IT201800002413A1 (it) | 2018-02-05 | 2019-08-05 | Carmine Antropoli | "composizione a base di nifedipina per uso nel trattamento delle ragadi anali e proctalgie" |
| BR102018008324A2 (pt) | 2018-04-25 | 2019-11-05 | Laboratorios Ferring Ltda | composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico |
| WO2019226542A1 (en) | 2018-05-22 | 2019-11-28 | Weinberg Assa | Methods for prevention and treatment of pressure ulcers caused by ischemia using contact vasodilators |
| CA3102228A1 (en) | 2018-06-01 | 2019-12-05 | Tavanta Therapeutics Hungary Incorporated | Topical amlodipine salts for the treatment of anorectal diseases |
-
2019
- 2019-05-29 CA CA3102228A patent/CA3102228A1/en active Pending
- 2019-05-29 ES ES19766349T patent/ES3030705T3/es active Active
- 2019-05-29 CN CN201980047697.9A patent/CN112423736A/zh active Pending
- 2019-05-29 WO PCT/IB2019/000689 patent/WO2019229535A2/en not_active Ceased
- 2019-05-29 IL IL279121A patent/IL279121B2/en unknown
- 2019-05-29 PL PL19766349.5T patent/PL3801460T3/pl unknown
- 2019-05-29 CR CR20200630A patent/CR20200630A/es unknown
- 2019-05-29 AU AU2019276832A patent/AU2019276832B2/en active Active
- 2019-05-29 JP JP2021517118A patent/JP7530354B2/ja active Active
- 2019-05-29 MX MX2020012949A patent/MX2020012949A/es unknown
- 2019-05-29 US US16/425,028 patent/US11197848B2/en active Active
- 2019-05-29 NZ NZ771464A patent/NZ771464A/en unknown
- 2019-05-29 KR KR1020207037931A patent/KR20210023908A/ko not_active Ceased
- 2019-05-29 BR BR112020024395-7A patent/BR112020024395A2/pt unknown
- 2019-05-29 HU HUE19766349A patent/HUE072422T2/hu unknown
- 2019-05-29 SG SG11202012365QA patent/SG11202012365QA/en unknown
- 2019-05-29 EP EP19766349.5A patent/EP3801460B1/en active Active
-
2020
- 2020-12-26 CO CONC2020/0016480A patent/CO2020016480A2/es unknown
-
2021
- 2021-07-16 US US17/305,916 patent/US11766428B2/en active Active
-
2023
- 2023-09-08 US US18/244,155 patent/US20230414591A1/en not_active Abandoned
-
2024
- 2024-11-07 US US18/940,485 patent/US20250064790A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11766428B2 (en) | 2023-09-26 |
| IL279121B2 (en) | 2024-06-01 |
| US20230414591A1 (en) | 2023-12-28 |
| EP3801460B1 (en) | 2025-03-12 |
| EP3801460C0 (en) | 2025-03-12 |
| WO2019229535A3 (en) | 2020-01-30 |
| HUE072422T2 (hu) | 2025-11-28 |
| NZ771464A (en) | 2024-12-20 |
| AU2019276832B2 (en) | 2024-08-15 |
| JP2021526554A (ja) | 2021-10-07 |
| US20250064790A1 (en) | 2025-02-27 |
| KR20210023908A (ko) | 2021-03-04 |
| CO2020016480A2 (es) | 2021-03-19 |
| IL279121B1 (en) | 2024-02-01 |
| CR20200630A (es) | 2021-05-26 |
| US20220000850A1 (en) | 2022-01-06 |
| US11197848B2 (en) | 2021-12-14 |
| EP3801460A2 (en) | 2021-04-14 |
| SG11202012365QA (en) | 2021-01-28 |
| CA3102228A1 (en) | 2019-12-05 |
| IL279121A (en) | 2021-01-31 |
| WO2019229535A2 (en) | 2019-12-05 |
| US20190365732A1 (en) | 2019-12-05 |
| MX2020012949A (es) | 2021-05-12 |
| CN112423736A (zh) | 2021-02-26 |
| AU2019276832A1 (en) | 2021-01-21 |
| JP7530354B2 (ja) | 2024-08-07 |
| ES3030705T3 (en) | 2025-07-01 |
| BR112020024395A2 (pt) | 2021-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280483A (en) | Muscle targeting complexes and uses thereof for treating pompe disease | |
| LT3672954T (lt) | Junginiai, jų druskos ir jų naudojimas ligoms gydyti | |
| IL281093A (en) | Combinations for treatment of nash/nafld and related diseases | |
| HUE066282T2 (hu) | Heterobiciklusos MAT2A-gátlók és eljárások rák kezelésében történõ alkalmazásukra | |
| PL3600309T3 (pl) | Skojarzenia terapeutyczne do leczenia chorób wątroby | |
| IL268850A (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| EP3601285A4 (en) | THERAPEUTIC AGENT FOR THE INHIBITION OF PHOSPHODIESTERASE AND ITS RELATED DISORDERS | |
| IL284125A (en) | Quinoline derivatives for use in the treatment of inflammation diseases | |
| IL282776A (en) | Plasmid constructs for treating cancer and methods of use | |
| HRP20181169T1 (hr) | Predlijekovi fumarata i njihova upotreba u liječenju različitih bolesti | |
| EP3914231A4 (en) | Treatment of skin disorders with topical tapinarof combination compositions | |
| EP3750553A4 (en) | THERAPEUTIC FOR PSORIASIS | |
| IL269158A (en) | Compositions and methods for treating inflammatory diseases | |
| IL281244A (en) | Combination therapy for the treatment of liver disease | |
| HUE060322T2 (hu) | Belélegezhetõ készítmények tüdõbetegségek kezelése során történõ alkalmazásra | |
| SI3947375T1 (sl) | Imidazolonilkinolinske spojine in terapevtske uporabe le-teh | |
| AR103118A1 (es) | Tratamientos médicos basados en anamorelina | |
| DK3722291T3 (da) | Indolinonforbindelser og deres anvendelse i behandlingen af fibrotiske sygdomme | |
| PL3801460T3 (pl) | Sole amlodypiny do stosowania miejscowego w leczeniu chorób odbytu i odbytnicy | |
| IL264407A (en) | Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases | |
| EP4203928A4 (en) | Inhalable therapeutic agents | |
| DK3784210T3 (da) | Topisk farmaceutisk sammensætning til behandling af analfissurer og hæmorider | |
| DK3986419T3 (da) | Boronsyre-derivater og terapeutiske anvendelser heraf | |
| IL282703A (en) | Novel compounds useful for treating cardiovascular diseases | |
| DK3937948T3 (da) | Phytoecdysoner og derivater deraf til anvendelse i behandlingen af neuromuskulære sygdomme |